Claritas Genomics

Founded in 1980, Amgen is one of the leading companies in the biotechnology industry. The company discovers, develops, manufactures and delivers human therapeutic products. It provides therapeutic services to treat a range of illnesses that includes cancers, kidney diseases and rheumatoid arthritis. Amgen also offers services to treat autoimmune diseases, such as psoriatic arthritis and ankylosing spondylitis. The company works with a team of more than 17,500 staff members. It is affiliated with Biotechnology industry Organization, Healthcare Leadership Council and Pharmaceutical Research manufacturers of America. Amgen conducts research programs related to inflammation, metabolism disorders, osteoporosis, neuroscience, oncology and hematology. Headquartered in Thousand Oaks, Calif., it maintains a location in West Greenwich, R.I.

Retlif Testing Laboratories is a leading provider of comprehensive testing services for industries such as commercial aviation, aerospace, rail transit, maritime, military, and commercial wireless. With multiple locations in Ronkonkoma, NY, Goffstown, NH, and Harleysville, PA, Retlif offers a wide range of services including EMC, EMI, ESS, and environmental engineering services, backed by their expertise and accreditations. With a commitment to excellence and a focus on delivering reliable results, Retlif Testing Laboratories sets itself apart in the industry. Their dedication to providing top-notch testing services, along with their extensive experience and state-of-the-art facilities, makes them a trusted choice for companies seeking reliable testing solutions.Generated from the website

Leap Therapeutics, based in Cambridge, MA, is dedicated to developing targeted and immuno-oncology therapeutics, with a focus on innovative treatments for various cancer types, including gastric, colorectal, and gynecologic cancers. Their lead candidate, DKN-01, is a humanized monoclonal antibody that targets the Dickkopf-1 (DKK1) protein and is currently in clinical development for patients with DKK1-expressing tumors. In addition to DKN-01, Leap Therapeutics is advancing FL-301, which targets Claudin18.2 for gastric and pancreatic cancers, and FL-501, a preclinical candidate that targets the growth and differentiation factor 15 (GDF-15) protein. The company is committed to understanding tumor expression and discovering new therapeutic targets and combinations to improve cancer treatment outcomes. Generated from the website